We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.26%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.91B
AUM Growth
-$2.56B
Cap. Flow
+$5.6B
Cap. Flow %
70.85%
Top 10 Hldgs %
34.65%
Holding
156
New
13
Increased
15
Reduced
59
Closed
23

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$7.7B
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$114M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$76.7M
4
FOLD
Amicus Therapeutics
FOLD
+$76.6M
5
SCPH
scPharmaceuticals
SCPH
+$48.1M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$172M
2
AET
Aetna Inc
AET
+$163M
3
BIIB icon
Biogen
BIIB
+$128M
4
MRK icon
Merck
MRK
+$108M
5
GILD icon
Gilead Sciences
GILD
+$107M

Sector Composition

Rank Sector Weight
1 Healthcare 91.1%
2 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMED
101
DELISTED
Amedisys
AMED
$10.9M 0.14%
+207,500
New +$10.9M
ELDN icon
102
Eledon Pharmaceuticals
ELDN
$261M
$10.3M 0.13%
140,951
– –
LAB icon
103
Standard BioTools
LAB
$318M
$9.33M 0.12%
1,583,700
-162,400
-9% -$889K
BMRN icon
104
BioMarin Pharmaceuticals
BMRN
$12B
$8.97M 0.11%
100,600
-643,300
-86% -$55.9M
KIDS icon
105
OrthoPediatrics
KIDS
$512M
$8.16M 0.1%
+425,200
New +$8.13M
AUPH icon
106
Aurinia Pharmaceuticals
AUPH
$1.92B
$8.14M 0.1%
1,797,400
– –
SYRE icon
107
Spyre Therapeutics
SYRE
$8.51B
$7.95M 0.1%
58,781
– –
ENDP
108
DELISTED
Endo International plc
ENDP
$7.94M 0.1%
+1,024,386
New +$7.67M
ALKS icon
109
Alkermes
ALKS
$8.31B
$7.94M 0.1%
145,000
– –
IRWD icon
110
CALL
Ironwood Pharmaceuticals
IRWD
$614M
$6M 0.08%
+477,600
New +$6.24M
GWPH
111
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.86M 0.07%
44,400
-516,671
-92% -$60.7M
TSRO
112
DELISTED
TESARO, Inc.
TSRO
$5.58M 0.07%
+67,281
New +$6.6M
SRPT icon
113
Sarepta Therapeutics
SRPT
$1.61B
$5.53M 0.07%
+99,400
New +$5.27M
MRNS
114
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.63M 0.06%
141,900
– –
PRQR icon
115
ProQR Therapeutics
PRQR
$246M
$4.2M 0.05%
1,302,955
-992,391
-43% -$3.56M
SNDX icon
116
Syndax Pharmaceuticals
SNDX
$1.7B
$3.83M 0.05%
437,000
– –
RDHL
117
Redhill Biopharma
RDHL
$4.26M
$2.9M 0.04%
565
– –
SRPT icon
118
CALL
Sarepta Therapeutics
SRPT
$1.61B
$2.78M 0.04%
50,000
-100,000
-67% -$5.3M
MCRB icon
119
Seres Therapeutics
MCRB
$45.8M
$2.23M 0.03%
10,973
– –
XENE icon
120
Xenon Pharmaceuticals
XENE
$6.26B
$1.79M 0.02%
634,812
– –
BHC icon
121
Bausch Health
BHC
$1.68B
$1.6M 0.02%
76,800
-118,100
-61% -$1.87M
BLRX
122
BioLineRX
BLRX
$12.3M
$1.13M 0.01%
1,731
– –
AFMD
123
DELISTED
Affimed
AFMD
$425K 0.01%
32,665
– –
ALIM
124
DELISTED
Alimera Sciences
ALIM
$333K ﹤0.01%
16,667
– –
NVLN
125
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$312K ﹤0.01%
100,000
– –
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2017 Portfolio in Review

As of Q4 2017, OrbiMed held 156 positions worth $7.91B, down 24% from $10.5B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed deployed $5.6B of net new capital in Q4 2017, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $163M trimmed.

  • OrbiMed's largest Q4 2017 buy was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.
  • OrbiMed added most to Loxo Oncology, Inc in Q4 2017, an estimated $7.7B increase.
  • OrbiMed's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $163M.
  • OrbiMed fully exited Incyte in Q4 2017, selling an estimated $172M.
  • OrbiMed's ten largest holdings make up 35% of its $7.91B portfolio in Q4 2017.
  • OrbiMed opened 13 new positions and closed 23 in Q4 2017.
  • OrbiMed's portfolio value fell 24% quarter-over-quarter to $7.91B.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.